[144] Akero Therapeutics, Inc. SEC Filing

Rhea-AI Filing Summary

Akero Therapeutics, Inc. (AKRO) Form 144 shows an insider sale notice for 56,369 shares of common stock to be sold through J.P. Morgan Securities LLC on 10/07/2025 with an aggregate market value of $2,595,229. The filing states these shares were acquired the same day via a stock option exercise and paid as compensation. The filer also reported two prior open-market sales this year: 12,500 shares on 08/05/2025 for $616,299 and 12,500 shares on 09/08/2025 for $552,135. The form includes the required representation that the seller does not possess undisclosed material adverse information and identifies the executing broker and the number of shares outstanding (79,988,975), enabling investors to see the scale of the disclosed sale relative to the company’s share count.

Positive

• Timely disclosure of the proposed sale via Form 144 for 56,369 shares
• Sale executed through a major broker (J.P. Morgan Securities LLC), indicating standard settlement channels
• Shares were acquired by option exercise and recorded as compensation, clarifying the source of securities

Negative

• None.

Insights

Insider Transactions Analyst

TL;DR: An insider is selling shares acquired by option exercise; the transaction is disclosed and routine.

The filing records a planned sale of 56,369 shares on 10/07/2025 executed through J.P. Morgan Securities LLC. The shares were acquired the same day via a stock option exercise and listed as compensation, which explains the insider source of the shares rather than a secondary purchase.

Risk dependencies include whether the sales follow a pre-arranged trading plan or are one-off dispositions; the form requires a representation about the absence of undisclosed material information but does not include a stated for any 10b5-1 plan. Monitor for any additional filings or plan-date disclosures in the near term.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	J.P. Morgan Securities LLC 390 Madison Avenue 6th Floor New York NY 10017	56369	2595229	79988975	10/07/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	10/07/2025	Stock Option Exercise	Issuer			56369	10/07/2025	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Timothy Rolph C/o Akero Therapeutics, Inc. 601 Gateway Boulevard, Suite 350 South San Francisco CA 94080	Common Stock	08/05/2025	12500	616299
Timothy Rolph C/o Akero Therapeutics, Inc. 601 Gateway Boulevard, Suite 350 South San Francisco CA 94080	Common Stock	09/08/2025	12500	552135

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the AKRO Form 144 report?

It reports an insider notice to sell 56,369 shares on 10/07/2025 with an aggregate market value of $2,595,229 via J.P. Morgan Securities LLC.

How were the 56,369 AKRO shares acquired?

The filing states the shares were acquired on 10/07/2025 through a stock option exercise, paid as compensation.

Has the insider sold AKRO shares recently?

Yes; the filer sold 12,500 shares on 08/05/2025 for $616,299 and 12,500 shares on 09/08/2025 for $552,135.

What portion of AKRO's outstanding shares does this sale represent?

The company has 79,988,975 shares outstanding; 56,369 shares are a small fraction of that total.

Does the filing state whether a 10b5-1 plan was used?

No explicit plan adoption date is provided in the filing; the form includes the standard representation about material information but does not list a 10b5-1 plan date.